HomePipelinePNB-091

Addiction research with NIDA

PNB-091

IND ready

Developed in collaboration with the US National Institute on Drug Abuse (NIDA) for drug abuse and addiction, with anxiolytic and antidepressant properties.

Indications

Each indication opens its study.

CNS & addiction

Stage of development

  • PNB-091

    Cocaine AddictionPan-CCK blocker

Graph of the stage of development of each PNB-091 programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Target and mechanism
Pan (dual) CCK antagonist with dopamine-pathway modulation.
Key findings

Active in anxiety and depression models (X-maze, black/white box, swim test). Locomotion studies, cocaine substitution and antagonism models were run in collaboration with NIDA.

Prevention of addiction was shown in intracranial self-stimulation assays in rats.

Development

Two-step synthesis, purity above 99.7%; stable in rat, dog and human liver microsomes. ICH toxicology studies are to be launched.

Intellectual property
Patents filed in the US, Europe and rest of world; USPTO patent issued 28 December 2014.

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.